Parkman Healthcare Partners LLC Purchases 76,334 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Parkman Healthcare Partners LLC boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 8.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,000,474 shares of the company’s stock after buying an additional 76,334 shares during the period. Day One Biopharmaceuticals accounts for approximately 1.7% of Parkman Healthcare Partners LLC’s holdings, making the stock its 21st biggest position. Parkman Healthcare Partners LLC owned about 0.99% of Day One Biopharmaceuticals worth $12,676,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Day One Biopharmaceuticals during the 4th quarter valued at $31,000. Tower Research Capital LLC TRC raised its holdings in shares of Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after purchasing an additional 9,603 shares during the last quarter. E Fund Management Co. Ltd. purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at approximately $143,000. KLP Kapitalforvaltning AS acquired a new position in Day One Biopharmaceuticals in the 4th quarter worth about $150,000. Finally, Man Group plc purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth $162,000. 87.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Needham & Company LLC lowered their price target on Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group reduced their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, March 25th. JPMorgan Chase & Co. cut their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Buy” and a consensus price target of $30.57.

Day One Biopharmaceuticals Trading Down 3.8%

Day One Biopharmaceuticals stock opened at $6.33 on Wednesday. The company has a fifty day simple moving average of $7.58 and a 200 day simple moving average of $10.97. The company has a market cap of $641.62 million, a P/E ratio of -6.15 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 1-year low of $6.10 and a 1-year high of $17.14.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analyst estimates of $30.28 million. On average, equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at approximately $1,531,059.40. This represents a 8.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the transaction, the general counsel now directly owns 39,602 shares of the company’s stock, valued at $473,639.92. This represents a 10.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock valued at $251,925 over the last ninety days. 6.20% of the stock is currently owned by insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.